Market revenue in 2023 | USD 3,399.3 million |
Market revenue in 2030 | USD 571.0 million |
Growth rate | -22.5% (CAGR from 2023 to 2030) |
Largest segment | Hospitals |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care |
Key market players worldwide | Becton Dickinson & Co, BioMerieux SA, Bio-Rad Laboratories Inc, Abbott Laboratories, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Roche Holding AG, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular diagnostics market will help companies and investors design strategic landscapes.
Hospitals was the largest segment with a revenue share of 47.15% in 2023. Horizon Databook has segmented the UK molecular diagnostics market based on hospitals, outpatient facilities, home care covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated healthcare infrastructure, high disposable income, and growing awareness about the benefits of early diagnosis are key drivers expected to propel the molecular diagnostics market in the UK. Demand for accurate & rapid diagnosis of cancer and other diseases is increasing.
Organizations such as the UK Genetics Testing Network are actively working to include genetic testing as an important asset in the NHS directory. It prepared a panel of genetic tests that formed the basis of certain rare diseases and cancer treatments. Furthermore, it has collaborated with NHS England to provide cost-effective genetic testing services.
The regulatory and reimbursement scenario is evolving to accommodate molecular testing, but uneven patient access to genomic testing remains a problem in this region. Prenatal genetic testing is performed primarily to identify the risk of developing genetic conditions by diagnosing genetic aberrations in the unborn.
Horizon Databook provides a detailed overview of country-level data and insights on the UK molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into UK molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account